B+
Bull case
25%
Probability
Target price
$66.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
TWST
Twist BioscienceFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The cleanest post-print positive is operational: 2Q26 revenue beat internal guidance, both DSPS and NGS grew year over year and sequentially, gross margin stayed above 50%, and management raised full-year revenue guidance while reiterating 4Q26 adjusted EBITDA breakeven [#8-K-2026-05-04].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Competition is intense across synthetic biology, gene synthesis, and NGS sample-prep markets, including providers such as GenScript, IDT/Danaher, Thermo Fisher, and Illumina; stronger incumbents can pressure pricing, product breadth, and turnaround times [#10-K-2025-11-17].
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $54.00 · Bull $66.00 · Bear $45.00Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $116.67
Why
Momentum99 · Δ7d -0.7
Value41 · Δ7d -0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Competition is intense across synthetic biology, gene synthesis, and NGS sample-prep markets, including providers such as GenScript, IDT/Danaher, Thermo Fisher, and Illumina; stronger incumbents can pressure pricing, product breadth, and turnaround times [#10-K-2025-11-17].
- • GAAP loss widened in 2Q26 and cash, cash equivalents, and short-term investments declined to about $172M at March 31, 2026, leaving limited room for execution misses if the breakeven timeline slips [#8-K-2026-05-04].
- • The near-term bear read is that stronger revenue did not translate into cleaner earnings quality: GAAP loss widened to $44.0M, cash fell to about $172M from about $198M at December 31, 2025, and the securities-settlement charge adds another overhang.
Catalyst clock
2026-05-12
Post-earnings digestion after revenue beat but EPS/litigation noise
Lead driver: Value · See fundamentals
Momentum
99
9% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-0.1
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 98.5 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$8.19B
Beta
2.23
Shares Out
65.83M
P/E (TTM) · Derived
-95.7
P/S (TTM)
5.58
P/FCF (TTM) · Derived
-81.76
Rev YoY
+23.2%
EPS YoY
-268.5%
Gross Margin
+52.0%
Op Margin
-31.9%
Net Debt
-$156.86M
Current Ratio
2.67
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data